drugset / Trial / NCT06056947

Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

NCT06056947

RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized, three-arms, multicentral study.

Timeline

Start
2020-07-20
Primary completion
2021-05-06
Completion
2021-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject fenticonazole Small molecule 600 mg Other
Subject tinidazole Small molecule 300 mg Other
Subject tinidazole Small molecule 1000 mg Other
Subject tinidazole Small molecule 2000 mg Other
Comparator tioconazole Small molecule 200 mg Other
Background Lidocaine Other / unclassified 100 mg Other